共 55 条
[1]
Ciccarelli A(2005)The epidemiology of prolactinomas Pituitary 8 3-6
[2]
Daly AF(2006)Advances in the treatment of prolactinomas Endocr Rev 27 485-534
[3]
Beckers A(2014)The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011 Eur J Endocrinol 171 519-526
[4]
Gillam MP(2014)Therapy of endocrine disease: the challenges in managing giant prolactinomas Eur J Endocrinol 170 213-227
[5]
Molitch ME(2013)Giant prolactinomas: the therapeutic approach Clin Endocrinol 79 447-456
[6]
Lombardi G(2000)CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas Clin Endocrinol 52 43-49
[7]
Colao A(2014)Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma Endocrinol Diabetes Metab Case Rep 2014 140020-295
[8]
Tjörnstrand A(2014)Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene? Hormones 13 290-387
[9]
Gunnarsson K(2011)Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma Pituitary 14 384-592
[10]
Evert M(2009)Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma Clin Endocrinol 70 588-71